The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Which patients could benefit most from post-HSCT maintenance therapy with daratumumab single agent?
Featured:
Philippe MoreauDuring the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, Which patients could benefit most from post-hematopoietic stem cell transplantation maintenance therapy with daratumumab single agent?
Which patients could benefit most from post-HSCT maintenance therapy with daratumumab single agent?
In this video, Moreau discusses the part two results of the phase III, randomized CASSIOPEIA study (NCT02541383), investigating the impact of daratumumab as maintenance compared with observation.